Axiom
ANALYTICS

CERTIFICATE OF ANALYSIS · 4X ESSENTIAL PANEL + 1 ADD-ON LAYER (L8)

Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US

**AX-2026-2686-SERB**

BPC-157 · Lot T-BPC-0032
Issued Oct 2, 2026 · v1
Verify: 2A14-ABCF-9D3A

SCAN TO VERIFY

## PASS — ALL SPECIFICATIONS MET

5 of 5 layers complete

| L1 | L2 | L3 | L4 | L8 |
|---|---|---|---|---|
| Identity | Purity | Net Peptide Content | Sterility | Fentanyl Screen |

## Sample & Vial Validation




Vial A: as received & analyzed

MORE VIEWS OF VIAL A



Vial A · right

| | | | |
|---|---|---|---|
| Client | **Liberty Research Solutions** | Product | **BPC-157** |
| Lot / Batch | **T-BPC-0032** | Label Claim | **10 mg** |
| Matrix | **lyophilized powder** | Sample Count | **1** |
| Cap Color | **Black** | Crimp Color | **Silver / Aluminum** |
| Contents Color | **White** | Seal Intact | **Yes** |
| Condition | **sealed, intact** | Received | **Sep 24, 2026** |
| Sampling | **client submitted** | | |

## Test Results

| Test | Specification | Result | |
|---|---|---|---|
| **Identity**<br>research screen | every vial within ±1 Da of 1419.556 Da | `1419.573 Da` | PASS |
| **Purity**<br>research screen | Expected Purity ≥ 99.25 area % · Acceptance NLT 99.25 area % · Units area % · Source Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31 | `99.57%` | PASS |
| **Net Peptide Content**<br>research screen | every vial within ±10% of 10 mg | `Vial A: 10.47 mg` | PASS |
| **Sterility · Rapid PCR**<br>research screen | Rapid PCR screen | `Target DNA not detected` | PASS |
| **Fentanyl Screen**<br>research screen | no fentanyl or analog at or above 1 ng/mg | `none detected` | PASS |

## Layer Results

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

Axiom
ANALYTICS

CERTIFICATE OF ANALYSIS · 4X ESSENTIAL PANEL + 1 ADD-ON LAYER (L8)

Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US

**AX-2026-2686-SERB**

BPC-157 · Lot T-BPC-0032
Issued Oct 2, 2026 · v1
Verify: 2A14-ABCF-9D3A

SCAN TO VERIFY

## 1 Identity

LC-MS (ESI+)


**1 physical-vial mass observation**
each +/- 1 Da (theor. 1419.556)

PASS

**Mass consistent with** BPC-157

Theoretical mass **1419.556 Da** Acceptance **+/- 1 Da**

| Vial | Observed mass | Mass error | Status |
|---|---|---|---|
| Vial A | 1419.573 Da | +0.017 Da | PASS |




## 2 Purity

RP-HPLC 214nm (USP 621)

**1 physical-vial purity observation**
Expected Purity ≥ 99.25 area % · Acceptance NLT 99.25 area % · Units area % · Source Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31

PASS

Expected Purity ≥ 99.25 area % · Acceptance NLT 99.25 area % · Units area % · Source Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31

| Vial | Purity | Status |
|---|---|---|
| Vial A | 99.57% | PASS |





## 3 Net Peptide Content

Quantitative HPLC vs reference std

**10.47 mg**
each within +/- 10% of 10 mg

PASS




| Vial | Measured | Status |
|---|---|---|
| Vial A | 10.47 mg | PASS |

## 4 Sterility

Rapid Microbial DNA Screen (qPCR target panel)

**Sterility · Rapid PCR: Target DNA not detected**
No microbial target DNA detected

PASS

**Sterility · Rapid PCR** PASS

Result **Target DNA not detected** Specification **Rapid PCR screen**

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US

**AX-2026-2686-SERB**

BPC-157 · Lot T-BPC-0032
Issued Oct 2, 2026 · v1
Verify: 2A14-ABCF-9D3A

SCAN TO VERIFY

## 8 Fentanyl Screen

LC-MS/MS targeted adulterant screen

**Not detected**
detection limit 1 ng/mg

PASS

| | | | |
|---|---|---|---|
| Analytes screened | **Fentanyl, Acetylfentanyl, Acrylfentanyl, Butyrylfentanyl, Carfentanil, Cyclopropylfentanyl, Furanylfentanyl, Methoxyacetylfentanyl, ortho-Fluorofentanyl, Valerylfentanyl, 4-ANPP (despropionyl fentanyl)** | Detection limit | **1 ng/mg** |
| Source container | **A** | | |

## Reporting Scope & Limitations

`[Sterility · Rapid PCR]` DNA-target research screen only. It detects microbial DNA from viable and non-viable organisms alike, and is neither viable-CFU enumeration under USP <61> nor a batch sterility determination under USP <71>.

`[Fentanyl Screen]` Targeted LC-MS/MS adulterant screen, reported as detected or not detected against its stated detection limit. A harm-reduction research screen, not an exhaustive adulterant panel.

## Digital Signatures

| | | | |
|---|---|---|---|
| Analyst | **Alana Reeves** | Analyst Signature | **ed25519:4e80a2fa42fd4e385654f1ab...** |
| Technical Reviewer | **Michael Niles** | Reviewer Signature | **ed25519:7ee550392a0d1cc5c4ae4ad9...** |
| Laboratory Director | **Daniel Brennan** | Director Signature | **ed25519:72011a7ff741e7593042877b...** |

Physical instrument analysis is performed within Axiom Analytics' laboratory network, allocated at Axiom's discretion based on method, capacity, and order volume. Axiom Analytics performs sample accession, chain of custody, analytical oversight, and data review, and issues and is responsible for this certificate. Where analysis is subcontracted, the method is performed within the partner laboratory's published ISO/IEC 17025 scope of accreditation for that method, not merely at a laboratory holding ISO/IEC 17025 accreditation. Axiom Analytics does not itself currently hold ISO/IEC 17025 accreditation. The method-validation status of each reported result is identified beside that result. Partner laboratory identities are not disclosed: samples are analyzed under double-blind conditions, identified only by an internal lot ID.

Each signature is an ed25519 signature over the SHA-384 hash of this report. Scan the QR on the letterhead or verify independently at https://axiomanalyticslab.com/verify/AX-2026-2686-SERB.

✓ **CRYPTOGRAPHICALLY SEALED (ed25519 + SHA-384)**

`SHA-384: 84766a3b348f70a22cda95bdfee9ab1d644d765f282b858df64a3c445c3c3453...`

`Seal: ed25519:4e1e9f9ed2a1d77a58f57bcf628a568f0c4aec93...`

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

**RESEARCH USE ONLY.** All analytical testing, validation reports, and interactive Certificates of Analysis (COAs) provided by Axiom Analytics are intended strictly for Research Use Only (RUO) in in-vitro or laboratory animal model environments. Axiom Analytics does not analyze, validate, evaluate, or make any representations regarding the safety, efficacy, toxicity, or legality of any tested substance for human or animal consumption, veterinary use, clinical diagnostics, food additives, cosmetics, or household applications.

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.